Allogeneic hematopoietic stem cell transplantation (AlloHSCT) is a powerful treatment modality that is frequently applied as part of treatment of hematological malignancies, aplastic anemia and inborn errors of hematopoietic progenitor cells. A major drawback of alloHSCT is the treatment related morbidity and treatment related mortality (TRM), which are largely accounted for by opportunistic infections. Those infections occur during a prolonged period (1-2 years), characterized by an impaired reconstitution of the adaptive immune system. Especially, the recovery of naïve T cells and thymopoiesis are protracted after transplantation, but are considered pivotal for restoration of anti-infectious immunity. This thesis has experimentally addressed new strategies that may improve thymopoiesis, including the post-transplant administration of cytokines that are physiologically involved in the differentiation and proliferation of thymocytes.
http://repub.eur.nl/res/pub/23627/110615_Wils%2C%20Evert-Jan_Bewerkt.pdf
No comments:
Post a Comment